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Abstract
Background: Endothelial cell dysfunction, by promoting fibrin deposition, has been implicated in
the development of multiple organ failure. Altered fibrinolysis during inflammation may participate
in microvascular alterations. We sought to determine whether plasma fibrinolysis was related to
the severity of organ dysfunction and/or to the levels of von Willebrand factor (vWF antigen), as a
marker of endothelium dysfunction, in critically ill patients.
Methods: Forty-nine consecutive patients admitted to an adult medico-surgical intensive care unit
(ICU) with (18) or without sepsis (31) were included. C-reactive protein and vWF levels were
measured on ICU admission and plasma fibrinolysis was assessed by the Euglobulin Clot Lysis Time
(ECLT). The sequential organ failure assessment (SOFA) score and the simplified acute physiology
score (SAPS) II were calculated on admission.
Results: ECLT was significantly longer in septic than in non-septic patients [1033 min (871–1372)
versus 665 min (551–862), p = 0.001]. There were significant correlations between ECLT and C-
reactive protein (CRP) concentrations (r = 0.78, p < 0.001) and the Sequential Organ Failure
Assessment (SOFA) score (r = 0.39, p = 0.006). The level of vWF was not correlated with the
ECLT (r = -0.06, p = 0.65) or the SOFA score (r = -0.02, p = 0.88).
Conclusion: ECLT measurement at admission could be a marker of organ dysfunction and a
prognostic indicator in critically ill patients.
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Introduction
Endothelial cells (ECs) are in tight contact with all organs,
so that EC activation and damage has been implicated in
the development of multiple organ failure (MOF) [1].
Among the proposed mechanisms, altered fibrinolysis
may promote fibrin deposition and thereby contribute to
microvascular alterations [2].
Fibrinolysis and inflammation may be intertwined. Ele-
vated concentrations of C-reactive protein (CRP), espe-
cially when they persist over time, are correlated with the
risk of MOF and death [3]. CRP may inhibit fibrinolysis
by inducing release of plasminogen activator inhibitor-1
(PAI-1) from human aortic ECs [4]. In addition, the
administration of recombinant CRP to volunteers
increases circulating PAI-1 levels [5]. We previously
showed that hypofibrinolysis assessed by the Euglobulin
Clot Lysis Time (ECLT) was strongly correlated with CRP
concentrations in critically ill patients [6].
ECLT is the test most commonly used to estimate plasma
fibrinolytic capacity. The ECLT result represents the bal-
ance between tissue plasminogen activator (t-PA) and
PAI-1 activities. We sought to define the relationship
between ECLT, as a marker of fibrinolysis, von Willebrand
factor (vWF), a marker of endothelial dysfunction [7], and
the severity of the clinical syndrome in critically ill
patients. Organ dysfunction was estimated by the Sequen-
tial Organ Failure Assessment (SOFA) score [8] and the
risk of hospital mortality by the simplified acute physio-
logic score (SAPS II) [9].
Materials and methods
Subjects
The study protocol was approved by the ethics committee
of A. Vésale hospital and informed consent was obtained
from each patient or their closest relative. Over a 5 month
period, we enrolled all consecutive critically ill patients at
ICU admission. Sepsis was defined by usual criteria [10].
Exclusion criteria were: age < 18 years, transfusion of red
blood cells or other blood components in the 72 h prior
to study entry, active bleeding, haematological disorders,
cytotoxic chemotherapy in the 6 months prior to study
entry, burns, cardiogenic shock, cirrhosis, or pregnancy.
The SAPS II score and SOFA scores were determined on
admission.
Blood samples
In each patient, blood samples were drawn once during
the 24 hours following ICU admission; serum and plasma
samples were obtained from the same venipuncture.
Serum samples were collected in vacuum tubes without
anticoagulant. Plasma samples were harvested in citrated
vacuum tubes and put in melting ice. Whole blood was
collected in EDTA-treated tubes. CRP was measured by
antibody-binding and turbidity measurement on SYN-
CHRON LX® (Analys, Belgium). Fibrinogen was deter-
mined by the Clauss method on a STA®  automate
(STAGO, Paris, France). An immuno-turbidimetric assay
for vWF determination was used (Liatest®  vWF:Ag,
STAGO, Paris France). Leucocytes and platelet counts
were determined using a haemocytometer (CELL-
DYN4000®, Abbott, Belgium).
Plasma fibrinolytic capacity
ECLT was measured on fresh plasma using a method
described elsewhere [11]. Briefly, we designed a com-
pletely computerized, semi-automatic, 8-channel device
for measurement and determination of fibrin clot lysis
(Lysis Timer, EREM, Belgium). The lysis time is evaluated
by mathematical analysis of the lysis curve and the results
are expressed in minutes (range: 5 to 9999). The efficiency
scores of the method are < 4% for intra-assay and < 7% for
inter-assay. Three hundred microlitres of acetic acid
(0.25%) and 3.6 ml of desionized water are added to 400
μl plasma (final pH≈5.9). The sample is then put into
melting ice for 20 min and centrifuged at 4000 g for 10
min at 4°C. The supernatant is discarded and the pellet is
resuspended in 400 μl of Owren-Koller buffer (DIAG-
NOSTICA STAGO®, France). Clot formation starts when
100 μl of thrombin (1.75 U/ml, DIAGNOSTICA STAGO®)
are added. Normal values are median 208 min (range,
118–303; n = 25) for men and median 117 min (range,
100–174; n = 21) for premenopausal women [11].
Statistics
We used SigmaStat® 3.5 (SPSS). The data are presented as
median value and range [25%–75%]. Correlations
between variables were analyzed using a Spearman corre-
lation test. A multiple logistic regression model was used
for survival analysis. A probability level of p < 0.05 was
considered as statistically significant.
Results
Of the 49 patients, 18 had sepsis (11 pneumonia, 2 peri-
tonitis, 2 skin infection, 1 urinary tract infection, 1 endo-
carditis and 1 mediastinitis); the 31 other patients had
exacerbated chronic obstructive pulmonary disease
(COPD) without evidence of sepsis (n = 21), postanoxic
coma or stroke (n = 6), or heart failure (n = 4). Mortality
was higher in septic than in non-septic patients (55% vs.
35.4%).
The biological characteristics of the patients are shown in
Table 1. Inflammatory variables, such as fibrinogen and
CRP levels, were higher in the septic than in the non-sep-
tic patients. ECLT was also higher in the septic than in the
non-septic patients. There was no significant difference in
vWF between septic and non-septic patients.
In the whole population, there was a significant correla-
tion between ECLT and CRP levels (n = 49, r = 0.678, p <Thrombosis Journal 2009, 7:10 http://www.thrombosisjournal.com/content/7/1/10
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0.001, fig 1A) and between ECLT and SOFA score (r =
0.39, p = 0.009, fig 1B). There was a weak correlation
between vWF and CRP levels (r = 0.29; p = 0.04), but not
between vWF and either ECLT (r = -0.06, p = 0.65) or the
SOFA score (r = -0.02, p = 0.88).
Table 2 shows the correlations between SOFA score, SAPS
II score, vWF levels and ECLT in non-septic and septic
patients. The relationship between SOFA score and ECLT
remained significant in the non-septic patients (r = 0.45,
p = 0.01) and was almost significant in the septic patients
(r = 0.39, p = 0.11). Other correlations were not signifi-
cant.
A multiple logistic regression model was used to evaluate
the ICU death event (Table 3). The SAPS II (p = 0.048) and
ECLT (p = 0.049) were retained in the multiple logistic
regression as explanatory variables for ICU mortality.
Discussion
Several studies have reported a relationship between coag-
ulation abnormalities, organ dysfunction and mortality in
critically ill patients [12-16], but the role of fibrinolysis
has not been well studied. Fibrinolytic activity is primarily
determined by the balance between t-PA and PAI-1 levels.
ECs are responsible for the production and release of t-PA
and contribute to the release of PAI-1. Multiple factors,
including lipoproteins, cytokines and inflammatory
markers, modulate EC production of t-PA and PAI-1 [17].
There are several reasons why decreased fibrinolysis could
be considered as a surrogate marker of EC dysfunction,
organ failure and mortality [18-20]. Indeed, the deposi-
tion of fibrin on confluent ECs causes EC aggregation and
disorganization of the monolayer, thus increasing perme-
ability [21,22]. In addition, fibrin is also a potent stimulus
for EC production and release of IL-8, a leucocyte chemo-
tactic factor [23].
In a large retrospective analysis of 1789 ICU patients,
Okabayashi et al [12] reported that the SOFA score was
correlated with antithrombin concentrations (r = 0.32, p
< 0.05), prothrombin fragment concentration (r = 0.4, p <
0.001) and fibrinolysis as assessed by t-PA-PAI-1 com-
plexes (r = 0.52, p < 0.001). Mavrommatis et al [24] stud-
ied the activation of fibrinolysis in septic patients during
the first day in the ICU, and observed that t-PA/PAI-1
complexes (4.7 ± 0.6 vs 2.1 ± 0.2 ng/mL) and the percent-
age of fibrinogen/fibrin degradation products (100 vs
57%) were higher in patients with septic shock than in
those without (all p < 0.001). These authors also observed
a greater activation of fibrinolysis, as reflected by
decreased plasminogen activity (41.6 ± 3.3 vs 87.4 ±
3.2%) and increased t-PA and PAI-1 concentrations [24].
ECLT is a global test for fibrinolysis, representing the bal-
ance between t-PA and PAI-1 activities. Previously consid-
ered as an imprecise method, we have been able to
improve the precision and reproducibility of the test with
a new semi-automatic device [11]. Moreover, in contrast
to that of vWF (12 h) [25], the half-lives of t-PA (3–4 min)
and PAI-1 (10 min) are very short, suggesting that ECLT
could be an instantaneous marker of clinical status. We
previously showed that ECLT was related to the number of
cardiovascular risk factors (hypertension, smoking habit,
Table 1: Population characteristics.





SAPS II 52.5 (45–63) 48 (38.5–64) 54 (49.2–62) 0.21
SOFA 7 (5.7–10) 6.5 (5–9) 8 (6–10.2) 0.41
ECLT (min) 791 (609–1023) 665 (551–862) 1033 (871–1372) < 0.001
vWF (%) 368 (293–490) 370 (289–450) 367 (294–513) 0.53
WBC (103/μl) 11 (8–14) 12.1 (8.3–14.3) 9.43 (7.7–16.3) 0.9
Haemoglobin (g/dl) 10.3 (8.7–12.2) 10.7 (9.4–12.7) 9.7 (8–11.2) 0.03
Haematocrit (%) 32.5 (27.2–37.1) 32.7 (29.3–38.5) 31.7 (25.2–33) 0.06
Activated clotting time (sec) 42 (35–48) 37.5 (32.5–45.5) 48 (45–51) < 0.001
Fibrinogen (g/l) 4.8 (3.73–6) 4.2 (3.5–5.08) 6.1 (4.6–8.1) 0.002
Prothrombin time (%) 70 (57–77) 73 (65–82) 61 (48.5–71.2) 0.006
Platelet count (103/μl) 70.5 (57.5–77) 250 (141–290) 267 (194–322) 0.27
Total bilirubin (mg/dl) 0.62 (0.41–0.91) 0.7 (0.42–0.96) 0.58 (0.39–0.85) 0.52
C-reactive protein (mg/dl 9.37 (4.4–23.4) 6.44 (2.8–11.8) 24.5 (15.5–34.6) < 0.001
Urea (mg/dl) 62.3 (40.05–78.15) 59 (39.6–75.1) 74 (44–78) 0.27
Creatinine (mg/dl) 1.02 (0.65–1.57) 1.01 (0.6–1.5) 1.3 (0.65–1.83) 0.59
ICU mortality 22 (42.3%) 11 (35.4%) 11 (55.5%) 0.05
Data shown as median (25%–75%), except for ICU mortality which is shown as absolute n (%). ECLT: Euglobulin Clot Lysis Time; WBC: White 
blood cells; SOFA: sequential organ failure assessment; SAPS: simplified acute physiology score; vWF: von Willebrand factorThrombosis Journal 2009, 7:10 http://www.thrombosisjournal.com/content/7/1/10
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diabetes, history of coronary event or stroke, menopausal
status) [26] and suggested that ECLT could be a surrogate
marker of endothelial dysfunction.
The present study confirms the previously described [6]
relationship between ECLT and CRP concentrations. This
relationship could be explained by the simple fact that
CRP reflects the severity of sepsis and the risk of organ fail-
ure. Alternatively, there may be a more pathophysiologic
explanation, as CRP can act directly on the endothelium
and modulates fibrinolysis [4,5]. Another mechanism for
the prolonged lysis time in septic patients could be related
to the effects of systemic inflammation on the liver, caus-
ing activation of various cells and release of cytokines
influencing the production of fibrinogen and PAI-1
[27,28].
We did not observe, in our population, a significant corre-
lation between ECLT and SAPS II score, as a severity score,
but the number of patients was limited and the mortality
was quite high in the non-septic group who had signifi-
cant co-morbidities.
Relationships between CRP, SOFA and ECLT (A and B respectively) Figure 1
Relationships between CRP, SOFA and ECLT (A and B respectively).Thrombosis Journal 2009, 7:10 http://www.thrombosisjournal.com/content/7/1/10
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Circulating plasma vWF is derived exclusively from the
endothelium (with some minor expression by megakary-
ocytes). vWF can be produced by ECs when they are stim-
ulated or damaged by various stimuli, including
inflammatory cytokines (e.g., interleukin-1 or tumour
necrosis factor), hypoxia, thrombin, histamine and leuco-
cyte elastase [29]. Increased levels of vWF are also influ-
enced by substances like adrenaline (epinephrine),
vasopressin, and even cyclosporin [29]. Plasma levels of
vWF have been considered as a marker of endothelial dys-
function and damage, although this is controversial [30]
and results from studies that have correlated plasma levels
of vWF, severity of inflammation and patient outcome are
inconsistent [30]. Ware et al [31] reported in 559 patients
with acute lung injury and/or with acute respiratory dis-
tress syndrome that vWF levels were not different in
patients with or without sepsis (p = 0.82). In contrast,
Kayal et al [32] observed that vWF plasma levels were sig-
nificantly higher in patients with severe infection (n = 25)
than in non-infected patients (n = 7) (p < 0.001). In the
present study, there was no significant difference in vWf
antigen between septic and non-septic patients. These
data confirm that vWF is a somewhat controversial marker
of sepsis.
Although, SAPS II and ECLT were retained as explanatory
variables of ICU mortality in the multiple logistic regres-
sion model, these results must be interpreted carefully in
light of the small sample size.
This study has some limitations, including the small sam-
ple size and the single-centre nature. Nevertheless, these
are interesting data and should be validated in larger het-
erogeneous populations.
In conclusion, ECLT measurements could represent a
marker of alterations in EC function and of organ dysfunc-
tion and may be a useful prognostic factor in critically ill
patients.
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